Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon P Moss

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
RMD Open|September 19, 2022
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunityCassandra Calabrese, Elizabeth Kirchner, Alexandra Villa-Forte, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 8, 2019
Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical settingLaura E Baldassari, Jenny Feng, Gabrielle Macaron, et al.
Journal of Neuroimmunology|July 25, 2022
Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case seriesJeffrey Lambe, Marisa P McGinley, Brandon P Moss, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 11, 2022
Perspectives and experiences with COVID-19 vaccines in people with MSJohn R Ciotti, Dana C Perantie, Brandon P Moss, et al.
Journal of Comparative Effectiveness Research|February 12, 2025
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims databaseAliza B Ben-Zacharia, Jenny J Feng, Brandon P Moss, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosisDeja R Rose, Ahmad Z Mahadeen, Alise K Carlson, et al.
Multiple Sclerosis and Related Disorders|November 24, 2019
Technology-enabled comprehensive characterization of multiple sclerosis in clinical practiceLaura E Baldassari, Kunio Nakamura, Brandon P Moss, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2020
Multiple sclerosis management during the COVID-19 pandemicBrandon P Moss, Kedar R Mahajan, Robert A Bermel, et al.
Neurology. Clinical Practice|July 10, 2020
Technology-enabled assessments to enhance multiple sclerosis clinical care and researchGabrielle Macaron, Brandon P Moss, Hong Li, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
RMD Open|September 19, 2022
Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunityCassandra Calabrese, Elizabeth Kirchner, Alexandra Villa-Forte, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 8, 2019
Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical settingLaura E Baldassari, Jenny Feng, Gabrielle Macaron, et al.
Journal of Neuroimmunology|July 25, 2022
Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case seriesJeffrey Lambe, Marisa P McGinley, Brandon P Moss, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 11, 2022
Perspectives and experiences with COVID-19 vaccines in people with MSJohn R Ciotti, Dana C Perantie, Brandon P Moss, et al.
Journal of Comparative Effectiveness Research|February 12, 2025
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims databaseAliza B Ben-Zacharia, Jenny J Feng, Brandon P Moss, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|December 20, 2021
Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosisDeja R Rose, Ahmad Z Mahadeen, Alise K Carlson, et al.
Multiple Sclerosis and Related Disorders|November 24, 2019
Technology-enabled comprehensive characterization of multiple sclerosis in clinical practiceLaura E Baldassari, Kunio Nakamura, Brandon P Moss, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2020
Multiple sclerosis management during the COVID-19 pandemicBrandon P Moss, Kedar R Mahajan, Robert A Bermel, et al.
Neurology. Clinical Practice|July 10, 2020
Technology-enabled assessments to enhance multiple sclerosis clinical care and researchGabrielle Macaron, Brandon P Moss, Hong Li, et al.
Pageof 2